SLC5A2 and type 2 diabetes mellitus: The apparent lack of effect on lipolysis in our study contrasts with data in patients with T2D where SGLT2 inhibition increased circulating NEFA and beta‐hydroxybutyrate.18 It has been postulated that increased lipolysis with SGLT2 inhibitors may be mediated through increased glucagon secretion,24 although circulating glucagon levels were not measured in the current study.